Xxizexxserxxce Xxmpaxx BV Pharmaceutical Import Profile — Czech Republic (DGFT 2022–2026)

Name: Xxizexxserxxce Xxmpaxx BV Pharmaceutical Import Records from India — 4 Products, $2.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxizexxserxxce Xxmpaxx BV — Pharmaceutical Importer Profile (2026) | 4 Products, $2.0M Trade | TransData Nexus

Xxizexxserxxce Xxmpaxx BV

Pharmaceutical Importer · Czech Republic · Oncology Focus · $2.0M Total Trade · DGFT Verified

Xxizexxserxxce Xxmpaxx BV is a pharmaceutical importer based in Czech Republic with a total trade value of $2.0M across 4 products in 2 therapeutic categories. Based on 41 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxizexxserxxce Xxmpaxx BV sources from 1 verified Indian supplier, with Zydus Hospira Oncology Private Limited accounting for 100.0% of imports.

Xxizexxserxxce Xxmpaxx BV — Import Portfolio & Supplier Network

Xxizexxserxxce Xxmpaxx BV import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxizexxserxxce Xxmpaxx BV?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Hospira Oncology Private Limited	$1.7M	52	100.0%

Xxizexxserxxce Xxmpaxx BV sources from 1 verified Indian supplier across 37 distinct formulations. The sourcing is highly concentrated — Zydus Hospira Oncology Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Gemcitabine injection 2g	$290.8K	6
Gemcitabine INJ. 200MG us -	$118.5K	3
Gemcitabine INJ.2g-br-h000205209	$109.5K	5
Oxaliplatin INJ. 100MG us	$100.0K	2
Gemcitabine INJ. 2g au/nz -	$100.0K	2
Oxaliplatin INJ. 100MG th	$96.7K	2
Irinotecan hcl INJ. 100MG-sg-f000054116	$60.0K	2
Oxaliplatin INJ.100MG-eg-f000057495	$50.0K	1
Gemcitabine injection 1g	$50.0K	1
Oxaliplatin INJ. 50MG jp	$50.0K	1
Gemcitabine INJ. 1g us n+	$50.0K	1
Docetaxel INJ.20MG-uspremier-f000052191	$50.0K	1
Cytarabine INJ. 2g	$50.0K	1
Bleo for INJ.USP 30unitsn+	$50.0K	1
Cytarabine injection 2g	$50.0K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gemcitabine	Oncology	$1.2M	24	2.6%	6
2	Oxaliplatin	Advanced Oncology	$500.0K	10	1.1%	10
3	Cytarabine	Advanced Oncology	$246.2K	5	2.3%	12
4	Docetaxel	Oncology	$100.0K	2	0.3%	13

Xxizexxserxxce Xxmpaxx BV imports 4 pharmaceutical products across 2 categories into Czech Republic totaling $2.0M.

Xxizexxserxxce Xxmpaxx BV — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxizexxserxxce Xxmpaxx BV is a pharmaceutical importer and buyer based in the Czech Republic. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. Over the period from 2022 to 2026, Xxizexxserxxce Xxmpaxx BV has imported a total of $2.0 million USD worth of pharmaceutical products from India, encompassing 41 shipments and 37 unique formulations across two therapeutic categories. The company's portfolio is heavily concentrated in oncology, with a significant focus on advanced oncology treatments.

2Distribution Network

While specific details about Xxizexxserxxce Xxmpaxx BV's warehouse locations and logistics capabilities are not publicly available, the company's substantial import activities suggest a well-established distribution network within the Czech Republic. The focus on oncology products indicates a targeted approach to meet the needs of healthcare providers and patients in this therapeutic area. The company's operations likely involve partnerships with local distributors and healthcare institutions to ensure efficient delivery and availability of imported pharmaceutical products.

3Industry Role

Xxizexxserxxce Xxmpaxx BV plays a significant role in the Czech Republic's pharmaceutical supply chain as a primary wholesaler and importer. By sourcing specialized oncology medications from India, the company addresses the demand for advanced cancer treatments within the Czech market. Its operations contribute to the diversification of the pharmaceutical supply, ensuring that healthcare providers have access to a broader range of therapeutic options.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxizexxserxxce Xxmpaxx BV

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, relying exclusively on a single supplier, ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED, for all its imports from India. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent volume of shipments and the exclusive focus on oncology products suggest a strategic partnership aimed at ensuring product quality and availability. The stability of this relationship is crucial for maintaining a reliable supply of specialized oncology medications in the Czech market.

2Supply Chain Resilience

Xxizexxserxxce Xxmpaxx BV's supply chain resilience is closely tied to its exclusive reliance on ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED. The lack of backup suppliers and the limited diversity in imported formulations may expose the company to risks associated with supply chain disruptions. Additionally, the company's focus on a narrow range of oncology products could limit its ability to adapt to changing market demands or regulatory requirements. Ensuring the regulatory compliance of its sole supplier and exploring opportunities to diversify its supplier base and product portfolio could enhance the company's supply chain resilience.

Strategic Implications

Importing Pharmaceuticals into Czech Republic — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Czech Republic

1Regulatory Authority & Framework

In the Czech Republic, the State Institute for Drug Control (SÚKL) serves as the primary regulatory authority overseeing the pharmaceutical sector. The legal framework governing pharmaceutical imports is primarily defined by Act No. 378/2007 Coll., on Pharmaceuticals, as amended, which outlines the requirements for marketing authorization, distribution, and quality control of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from SÚKL, ensuring compliance with EU standards, and adhering to the specific regulations set forth by the Czech authorities.

2Import Licensing & GMP

Import licensing in the Czech Republic requires compliance with EU Good Manufacturing Practice (GMP) standards. Indian exporters must ensure that their manufacturing facilities are certified by recognized bodies such as the European Medicines Agency (EMA) or the World Health Organization (WHO). Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of medicinal products within the Czech market. This authorization ensures that distributors adhere to the regulatory requirements set by SÚKL and maintain the integrity of the pharmaceutical supply chain.

Quality & Labeling

Xxizexxserxxce Xxmpaxx BV — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxizexxserxxce Xxmpaxx BV's focus on oncology, particularly advanced oncology treatments, aligns with the growing demand for specialized cancer therapies in the Czech Republic. The importation of high-value products like Gemcitabine and Oxaliplatin indicates a strategic emphasis on addressing critical therapeutic needs. This product strategy positions the company to serve a niche market segment, catering to healthcare providers and patients requiring advanced oncology medications.

2Sourcing Profile

The company's sourcing strategy is centered on high-quality generic drugs, with a preference for formulations that meet EU GMP standards. India's established reputation in the production of generic pharmaceuticals makes it a suitable partner for Xxizexxserxxce Xxmpaxx BV. The company's exclusive reliance on a single supplier reflects a strategic choice to ensure product consistency and quality, albeit with potential risks associated with supply chain concentration.

3Market Positioning

Based on its product mix, Xxizexxserxxce Xxmpaxx BV primarily serves the hospital and specialized healthcare sectors within the Czech Republic. The focus on advanced oncology treatments suggests partnerships with oncology centers, hospitals, and clinics that require access to specialized cancer therapies. The company's role as a wholesaler and importer positions it as a key player in the distribution of critical medicinal products to healthcare providers.

Seller's Guide — How to Become a Supplier to Xxizexxserxxce Xxmpaxx BV

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Czech market by offering high-quality oncology products that meet EU GMP standards. To succeed, suppliers must navigate the regulatory landscape, establish relationships with distributors like Xxizexxserxxce Xxmpaxx BV, and demonstrate the reliability and efficacy of their products. Diversifying the supplier base could also mitigate risks associated with single-source dependency and enhance supply chain resilience.

2Requirements & Qualifications

Indian exporters aiming to supply Xxizexxserxxce Xxmpaxx BV and the broader Czech market must obtain marketing authorization from SÚKL, ensuring compliance with EU GMP standards. Products must undergo batch testing, meet stability requirements, and adhere to labeling regulations in the Czech language. Additionally, obtaining wholesale distribution authorization is necessary to operate within the Czech pharmaceutical supply chain.

3How to Approach

Frequently Asked Questions — Xxizexxserxxce Xxmpaxx BV

What products does Xxizexxserxxce Xxmpaxx BV import from India?

Xxizexxserxxce Xxmpaxx BV imports 4 pharmaceutical products across 2 categories. Top imports: Gemcitabine ($1.2M), Oxaliplatin ($500.0K), Cytarabine ($246.2K), Docetaxel ($100.0K).

Who supplies pharmaceuticals to Xxizexxserxxce Xxmpaxx BV from India?

Xxizexxserxxce Xxmpaxx BV sources from 1 verified Indian suppliers. The primary supplier is Zydus Hospira Oncology Private Limited (100.0% of imports, $1.7M).

What is Xxizexxserxxce Xxmpaxx BV's total pharmaceutical import value?

Xxizexxserxxce Xxmpaxx BV's total pharmaceutical import value from India is $2.0M, based on 41 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxizexxserxxce Xxmpaxx BV focus on?

Xxizexxserxxce Xxmpaxx BV imports across 2 categories. The largest: Oncology (63.5%), Advanced Oncology (36.5%).

Get Full Xxizexxserxxce Xxmpaxx BV Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.